EndoSphere Inc., a Columbus, Ohio-based medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, completed a Series A financing round.
The round, whose amount remained undisclosed, was led by Broadline Capital, with participation from Glengary LLC, Physician Investment Group LLC, and large angel investment funds including Ohio TechAngel Funds II and III, North Coast Angel Fund II, and QCA First Fund III.
The company intends to use the funding to expand its intellectual property assets and to complete additional clinical product testing. EndoSphere holds 23 U.S. and international issued and pending patents.
Founded in 2006 and led by CEO James McKinley, EndoSphere CEO EndoSphere develops and commercializes devices that treats obesity and its co-morbidities.